
The aims of this review are zzso to examine the zzso relationship between type 2 diabetes and zzso zzso to provide an overview of current and emerging treatments for type 2 diabetes and their effects on body zzso 

A zzso search was performed for literature published in the English language from 1966 to zzso zzso and presentations from the American Diabetes Association Scientific Sessions zzso and the European Association for the Study of Diabetes Annual zzso zzso were also searched for relevant zzso zzso and clinical data were selected for inclusion based on novelty and zzso to treatment of the obese zzso 

Recent guidelines suggest that all patients with type 2 diabetes should initially receive zzso as well as lifestyle intervention, followed by rapid administration of other oral zzso agents or insulin if zzso goals are not met or zzso Many oral zzso drugs, and insulin, are associated with weight zzso New agents with zzso activity that may be advantageous in obese patients with type 2 diabetes have recently become zzso These include zzso zzso zzso which reduce blood zzso while reducing body weight but commonly cause zzso and zzso A new class of oral agents, the zzso zzso zzso is zzso and largely devoid of gastrointestinal zzso The zzso zzso zzso zzso is the first of a new class of zzso agents that reduces central obesity and improves multiple aspects of vascular zzso 

New agents offer the prospect of improved zzso control without weight zzso However, the ultimate roles of these agents in the treatment of obese patients with type 2 diabetes remain to be zzso 

